928846-98-4

Usage

Uses

Used in Pharmaceutical Research and Development:
[5-(2-AMINO-PHENYL)-THIOPHEN-2-YL]-ACETIC ACID METHYL ESTER is used as a building block in the pharmaceutical industry for the development of new drugs. Its unique structure allows for further modifications to improve the compound's biological activity and therapeutic potential.
Used in Drug Delivery Systems:
In the field of drug delivery, [5-(2-AMINO-PHENYL)-THIOPHEN-2-YL]-ACETIC ACID METHYL ESTER is utilized to enhance the efficiency and effectiveness of drug administration. Its structural properties make it a promising candidate for the design of innovative drug delivery systems, potentially improving the bioavailability and targeted delivery of therapeutic agents.
Used in Organic Synthesis:
[5-(2-AMINO-PHENYL)-THIOPHEN-2-YL]-ACETIC ACID METHYL ESTER is employed as a key component in organic synthesis, where it can be used to create a variety of complex molecules with diverse applications across different industries.
Used in Therapeutic Applications:
[5-(2-AMINO-PHENYL)-THIOPHEN-2-YL]-ACETIC ACID METHYL ESTER is also used as a therapeutic agent in the medical field, thanks to its studied anti-inflammatory and analgesic properties. These characteristics make it a potential candidate for the treatment of various conditions that involve inflammation and pain.

Upstream product

• 67137-56-8 (5-bromo-thiophen-2-yl)-acetic acid methyl ester 
• 19432-68-9 methyl 2-thiopheneacetate 

Downstream Products

• 934176-29-1 (5-{2-[3-(3,4,5-trimethoxy-phenyl)-propionylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934176-43-9 (5-{2-[2-(2,3,4-trimethoxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934176-26-8 (5-{2-[2-(3,4,5-trimethoxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934176-50-8 (5-{2-[3-(2,3,4-trimethoxy-phenyl)-propionylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934176-56-4 (5-{2-[3-(2,3,4-trimethoxy-phenyl)-acryloylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934176-52-0 (5-{2-[3-(3,4,5-trimethoxy-phenyl)-acryloylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 934247-59-3 C₂₉H₂₇NO₆S 
• 934176-82-6 (5-{2-[2-(2',3',4'-trimethoxy-biphenyl-3-yl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid 
• 934176-72-4 (5-{2-[(2',3',4'-trimethoxy-biphenyl-4-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid 
• 928847-12-5 (5-{2-[(3',4',5'-trimethoxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid 
• 928847-14-7 (5-{2-[(3',4',5'-trimethoxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid 
• 928847-17-0 (5-{2-[(2',3',4'-trimethoxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid 

Relevant academic research and scientific papers

Novel Hydroxylated Aromatic Compounds

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

Rational design of novel, potent small molecule pan-selectin antagonists

This report describes the first results of a rational hit-finding strategy to design novel small molecule antiinflammatory drugs targeting selectins, a family of three cellular adhesion molecules. Based on recent progress in understanding of molecular interaction between selectins and their natural ligands as well as progress in clinical development of synthetic antagonists like 1 (bimosiamose, TBC1269), this study was initiated to discover small molecule selectin antagonists with improved pharmacological properties. Considering 1 as template structure, a ligand-based approach followed by focused chemical synthesis has been applied to yield novel synthetic small molecules (MWr 500) with a trihydroxybenzene motif, bearing neither peptidic nor glycosidic components, with nanomolar in vitro activity. Biological evaluation involves two kinds of in vitro assays, a static molecular binding assay, and a dynamic HL-60 cell attachment assay. As compared to controls, the novel compounds showed improved biological in vitro activity both under static and dynamic conditions.

NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY

Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.